Thus, DNMT3A mutation can interact directly and indirectly with CDK1 to promote CDK1 function and restrain EZH2 function, which suggests that CDK1 can promote DNMT3A mutation-related AML progression in multiple ways. This evidence concerns the gene EZH2 and acute myeloid leukemia.